[Idiopathic hyperaldosteronism (IHA)].
Miyashita K, Itoh H, Nakao K.
Nihon Rinsho. 2006 May 28;Suppl 1:624-7.
The Value of Targeting CXCR4 With 68Ga-Pentixafor PET/CT for Subtyping Primary Aldosteronism.
Zheng Y, Long T, Peng N, Zhen M, Ye Q, Zhang Z, He Y, Chen Z, Gan Y, Luo M, Li C, Liu Z, Guo M, Wang M, Luo X, Hu S, Liu L, Jiang T.
J Clin Endocrinol Metab. 2023 Dec 21;109(1):171-182. doi: 10.1210/clinem/dgad421.
Hyperaldosteronism in pregnancy.
Escher G.
Ther Adv Cardiovasc Dis. 2009 Apr;3(2):123-32. doi: 10.1177/1753944708100180. Epub 2009 Jan 26.
Cellular and Genetic Causes of Idiopathic Hyperaldosteronism.
Omata K, Satoh F, Morimoto R, Ito S, Yamazaki Y, Nakamura Y, Anand SK, Guo Z, Stowasser M, Sasano H, Tomlins SA, Rainey WE.
Hypertension. 2018 Oct;72(4):874-880. doi: 10.1161/HYPERTENSIONAHA.118.11086.
Characterization of Aldosterone-producing Cell Cluster (APCC) at Single-cell Resolution.
Iwahashi N, Umakoshi H, Seki T, Gomez-Sanchez CE, Mukai K, Suematsu M, Umezawa Y, Oya M, Kosaka T, Seki M, Suzuki Y, Horiuchi Y, Ogawa Y, Nishimoto K.
J Clin Endocrinol Metab. 2022 Aug 18;107(9):2439-2448. doi: 10.1210/clinem/dgac394.
Adrenal venous sampling: cosyntropin stimulation or not?
Deinum J, Groenewoud H, van der Wilt GJ, Lenzini L, Rossi GP.
Eur J Endocrinol. 2019 Sep;181(3):D15-D26. doi: 10.1530/EJE-18-0844.
Comparisons of risk factors for post-treatment renal dysfunction between the two major subtypes of primary aldosteronism.
Watanabe D, Morimoto S, Morishima N, Ichihara A.
Endocrine. 2024 Apr;84(1):245-252. doi: 10.1007/s12020-023-03627-w. Epub 2023 Dec 12.
Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism.
Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, Kurihara I, Umakoshi H, Ichijo T, Katabami T, Wada N, Ogawa Y, Yoshimoto T, Kawashima J, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Miyauchi S, Kamemura K, Fukuoka T, Yamamoto K, Otsuki M, Suzuki T, Naruse M; JPAS Study Group.
J Clin Endocrinol Metab. 2018 Dec 1;103(12):4456-4464. doi: 10.1210/jc.2018-00866.
Safety and efficacy of bilateral superselective adrenal arterial embolization for treatment of idiopathic hyperaldosteronism: a prospective single-center study.
Mao M, Feng R, Khan NA, Tao L, Tang P, Zhao Y, Chen J, Li X, Zhao H, Shi Q, Wang L, Lyu F, Asghar MA, He Y, Chang J, Xiang R.
BMC Surg. 2024 Aug 24;24(1):242. doi: 10.1186/s12893-024-02530-z.
Superselective adrenal arterial embolization for idiopathic hyperaldosteronism: 12-month results from a proof-of-principle trial.
Dong H, Zou Y, He J, Deng Y, Chen Y, Song L, Xu B, Gao R, Jiang X.
Catheter Cardiovasc Interv. 2021 May 1;97 Suppl 2:976-981. doi: 10.1002/ccd.29554. Epub 2021 Feb 19.
